Vir Biotechnology, Inc. — Director's Dealing 2021

Feb 18, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-02-16

Reporting Person: Virgin Herbert (EVP, Research & CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-16	Common Stock	A	30000	$0.00	Acquired	63200	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-16	Stock Option (Right to Buy)	$67.38	A	60000	Acquired	2031-02-15	Common Stock (60000)	Direct

Footnotes

F1: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.

F2: 1/4 of the shares subject to the stock option vest and become exercisable on February 16, 2022, and the remainder vest in 36 equal monthly installments thereafter.